Treatment of aggressive pituitary tumours and carcinomas : results of a European Society of Endocrinology (ESE) survey 2016
OBJECTIVE: To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment.DESIGN: Electronic survey to ESE members Dec 2015-Nov 2016.RESULTS: Reports on 166 patients (40 PC, 125 APT, 1 unclassified) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% of the tumours were